Obesity/Overweight – Epidemiology – Emerging Markets

Clarivate Epidemiology’s coverage of obesity/overweight comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of obesity/overweight for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.

Clarivate Epidemiology’s obesity/overweight forecast will answer the following questions:

  • Of all people with obesity/overweight, how many in each of the major mature pharmaceutical markets have been formally diagnosed?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of obesity/overweight over the forecast period?

All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

In total, Clarivate Epidemiology forecasts 10 obesity/overweight patient populations, as follows:

  • Diagnosed prevalent cases of overweight/obesity.
  • Undiagnosed prevalent cases of overweight/obesity.
  • Prevalent cases of obesity.
  • Prevalent cases of class I obesity.
  • Prevalent cases of class II obesity.
  • Prevalent cases of class III obesity.
  • Prevalent cases of overweight.
  • Drug-treatable prevalent cases of overweight.
  • Diagnosed drug-treated prevalent cases of obesity.
  • Diagnosed non-drug-treated prevalent cases of obesity.

Note: Coverage may vary by country.